6-ethynyl-3H-imidazo[4,5-b]pyridine | 351325-04-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 6-ethynyl-3H-imidazo[4,5-b]pyridine
• 英文别名: 6-Ethynyl-1H-imidazo[4,5-b]pyridine
• CAS: 351325-04-7
• 化学式: C₈H₅N₃
• mdl: MFCD13177375
• 分子量: 143.148
• InChiKey: YPNIXMJEIIWTKT-UHFFFAOYSA-N

物化性质

• 沸点：
  421.5±25.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-ethynyl-3H-imidazo[4,5-b]pyridine 、 N-[4-(4-ethyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-3-iodo-4-methyl-benzamide 在 copper(l) iodide 、 四(三苯基膦)钯 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-imidazo[4,5-b]pyridin-6-yl)ethynyl]-4-methylbenzamide
  参考文献：
  名称：

  Broad spectrum alkynyl inhibitors of T315I Bcr-Abl

  摘要：

  A series of alkyne-containing type II inhibitors with potent inhibitory activity of T315I Bcr-Abl has been identified. The most active compound 4 exhibits an EC(50) of less than 1 nM against wild-type Bcr-Abl and an EC50 of 10 nM against T315I mutant but is broadly active against a number of other kinases. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.05.043
• 作为产物：
  描述：

  6-trimethylsilanylethynyl-3H-imidazo[4,5-b]pyridine 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 反应 0.25h， 以91%的产率得到6-ethynyl-3H-imidazo[4,5-b]pyridine
  参考文献：
  名称：

  取代四氢化萘酰胺类化合物及其药学上可接 受的盐及制备方法和应用

  摘要：

  本发明涉及通式为Ⅰ所示的取代四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用。做为一种抗肿瘤药物，本发明还提供了这类化合物的制备方法，以及含有它们的药物组合物，体外、体内的抗肿瘤作用研究结果和急性毒性研究结果，本发明得到的抗肿瘤药物取代苯并环酰胺类化合物，具有更优良的抗肿瘤活性和安全性，尤其是抗伊马替尼耐药的肿瘤，可在治疗白血病、胃肠道间质瘤、肺癌、结肠癌、卵巢癌及肾癌等肿瘤中的应用，因而治疗窗宽，所以在医药领域中作为抗肿瘤剂是非常有应用价值的。

  公开号：

  CN104250253B

文献信息

• [EN] 5-ALKYNYL-PYRIMIDINES<br/>[FR] 5-ALCYNYL-PYRIMIDINES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010012740A1

  公开（公告）日：2010-02-04

  The present invention encompasses compounds of general Formula (1) wherein R1 to R4 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

  本发明涵盖了一般式（1）中R1至R4如权利要求1所定义的化合物，适用于治疗以细胞过度增殖或异常增殖为特征的疾病，并用于制备具有上述特性的药物。
• Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
  申请人：——

  公开号：US20020103203A1

  公开（公告）日：2002-08-01

  Amide compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  描述了调节和/或抑制特定蛋白激酶活性的酰胺化合物。这些化合物和含有它们的药物组合物能够介导酪氨酸激酶信号传导，以调节和/或抑制不需要的细胞增殖。该发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予这些化合物的有效量来治疗癌症以及与不需要的血管生成和/或细胞增殖相关的其他疾病状态，如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣的方法。
• 5-ALKYNYL-PYRIMIDINES
  申请人：SCHNEIDER Siegfried

  公开号：US20120028952A1

  公开（公告）日：2012-02-02

  The present invention encompasses compounds of general formula (1) wherein R 1 to R 3 are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

  本发明涵盖了一般式（1）中定义的化合物，其中R1至R3如权利要求1中所定义，适用于治疗以细胞过度或异常增殖为特征的疾病，并用于制备具有上述特性的药物。
• [EN] 5-ALKYNYL PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS<br/>[FR] 5-ALCYNYL PYRIMIDINES ET LEUR UTILISATION COMME INHIBITEURS DE KINASES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2011092197A1

  公开（公告）日：2011-08-04

  The present invention encompasses compounds of general formula (1) wherein R1 to R4 R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

  本发明涵盖了一般式（1）中R1至R4 R3如权利要求1所定义的化合物，这些化合物适用于治疗以细胞过度或异常增殖为特征的疾病，并用于制备具有上述特性的药物。
• [EN] 5-ALKYNYL-PYRIDINES<br/>[FR] 5-ALCYNYLPYRIDINES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010122069A1

  公开（公告）日：2010-10-28

  The present invention encompasses compounds of general Formula (I), wherein R1 to R4, m and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

  本发明涵盖了一般式(I)的化合物，其中R1至R4、m和n的定义如权利要求书中所述，适用于治疗以细胞过度或异常增殖为特征的疾病，并用于制备具有上述特性的药物。